Have a feature idea you'd love to see implemented? Let us know!

GILD Gilead Sciences Inc

Price (delayed)

$92.57

Market cap

$115.37B

P/E Ratio

925.7

Dividend/share

$3.08

EPS

$0.1

Enterprise value

$133.58B

Gilead Sciences, Inc. /ˈɡɪliəd/, is an American biopharmaceutical company headquartered in Foster City, California that researches, develops and commercializes drugs. The company focuses primarily on antiviral drugs used in the ...

Highlights
Gilead Sciences's debt has decreased by 7% YoY
GILD's revenue is up by 3.3% year-on-year
The quick ratio has grown by 19% from the previous quarter but it has contracted by 16% YoY
The company's net income has shrunk by 98% YoY and by 88% QoQ
GILD's EPS has dropped by 98% year-on-year and by 88% since the previous quarter

Key stats

What are the main financial stats of GILD
Market
Shares outstanding
1.25B
Market cap
$115.37B
Enterprise value
$133.58B
Valuations
Price to book (P/B)
6.24
Price to sales (P/S)
4.08
EV/EBIT
114.17
EV/EBITDA
33.97
EV/Sales
4.72
Earnings
Revenue
$28.3B
Gross profit
$21.54B
Net income
$126M
EBIT
$1.17B
EBITDA
$3.93B
Free cash flow
$9.43B
Per share
EPS
$0.1
EPS diluted
$0.08
Free cash flow per share
$7.56
Book value per share
$14.84
Revenue per share
$22.69
TBVPS
$20.58
Balance sheet
Total assets
$54.53B
Total liabilities
$36.14B
Debt
$23.25B
Equity
$18.48B
Working capital
$3.05B
Liquidity
Debt to equity
1.26
Current ratio
1.26
Quick ratio
0.82
Net debt/EBITDA
4.63
Margins
EBITDA margin
13.9%
Gross margin
76.1%
Net margin
0.4%
Operating margin
2.9%
Efficiency
Return on assets
0.2%
Return on equity
0.7%
Return on invested capital
3.6%
Return on capital employed
2.7%
Return on sales
4.1%
Dividend
Dividend yield
3.33%
DPS
$3.08
Payout ratio
3,080%

GILD stock price

How has the Gilead Sciences stock price performed over time
Intraday
1.62%
1 week
0.78%
1 month
4.45%
1 year
17.79%
YTD
14.27%
QTD
10.41%

Financial performance

How have Gilead Sciences's revenue and profit performed over time
Revenue
$28.3B
Gross profit
$21.54B
Operating income
$821M
Net income
$126M
Gross margin
76.1%
Net margin
0.4%
The company's net income has shrunk by 98% YoY and by 88% QoQ
Gilead Sciences's net margin has shrunk by 98% YoY and by 89% QoQ
The operating margin has plunged by 90% YoY and by 68% from the previous quarter
The operating income has dropped by 90% year-on-year and by 68% since the previous quarter

Growth

What is Gilead Sciences's growth rate over time

Valuation

What is Gilead Sciences stock price valuation
P/E
925.7
P/B
6.24
P/S
4.08
EV/EBIT
114.17
EV/EBITDA
33.97
EV/Sales
4.72
GILD's EPS has dropped by 98% year-on-year and by 88% since the previous quarter
The stock's price to book (P/B) is 42% more than its 5-year quarterly average of 4.4 and 25% more than its last 4 quarters average of 5.0
Gilead Sciences's equity has decreased by 17% YoY
GILD's price to sales (P/S) is 20% more than its 5-year quarterly average of 3.4 and 17% more than its last 4 quarters average of 3.5
GILD's revenue is up by 3.3% year-on-year

Efficiency

How efficient is Gilead Sciences business performance
GILD's return on assets has dropped by 98% year-on-year and by 89% since the previous quarter
The company's return on equity has shrunk by 97% YoY and by 87% QoQ
GILD's return on sales has dropped by 86% year-on-year and by 55% since the previous quarter
Gilead Sciences's ROIC has plunged by 85% YoY and by 53% from the previous quarter

Dividends

What is GILD's dividend history
DPS
$3.08
Dividend yield
3.33%
Payout ratio
3,080%
Recent dividends

Special dividends are included in TTM DPS and yield

Financial health

How did Gilead Sciences financials performed over time
GILD's total assets is 51% higher than its total liabilities
The quick ratio has grown by 19% from the previous quarter but it has contracted by 16% YoY
GILD's total assets is down by 13% YoY
Gilead Sciences's debt is 26% higher than its equity
Gilead Sciences's equity has decreased by 17% YoY
The company's debt to equity rose by 13% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from and Sharadar.